Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Research

Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis

Prostate Cancer and Prostatic Diseases volume 18, pages 110–121 (2015)Cite this article

Subjects

Abstract

Background:

Conflicting evidence exists regarding the beneficial effects of metformin in prostate cancer. To determine the association between metformin and clinical outcomes in prostate cancer using systematic review and meta-analysis.

Methods:

Original articles published in English until third week of July, 2014 were searched in electronic databases (Medline-Ovid, Scopus, The Cochrane Library, Web of Science, ProQuest) for studies on metformin use in prostate cancer. The clinical outcomes assessed were: development of biochemical recurrence, metastases or castration-resistant metastatic cancer, all-cause and prostate cancer-specific mortality. Meta-analysis was performed to calculate the pooled hazard ratio (pHR) and their 95% confidence interval (95% CI). Heterogeneity between the studies was examined using I2 statistics. Sensitivity analysis was conducted to assess the robustness of findings and publication bias was assessed by the Egger’s regression asymmetry test and contour plot.

Results:

Out of 230 retrieved citations, eight retrospective cohort studies and one nested-case-control study met the inclusion criteria. Metformin use was marginally associated with reduction in the risk of biochemical recurrence (pHR: 0.82, 95% CI: 0.67, 1.01, P-value=0.06, I2=25%, five studies). Metformin use was not significantly associated with metastases (pHR: 0.59, 95% 0.30–1.18, P-value=0.14, I2=74%, three studies), all-cause mortality (pHR: 0.86; 95% CI, 0.67, 1.10, P-value=0.23, I2: 73%, six studies) and prostate cancer-specific mortality (pHR: 0.76, 95% CI: 0.43, 1.33, P-value = 0.33, I2=60%, four studies). Pooled estimates for all outcomes varied in sensitivity analysis by diabetes status and primary treatment of prostate cancer. Systematic review revealed mixed findings on metformin use and the risk of CRPC.

Conclusions:

Metformin may reduce the risk of biochemical recurrence in prostate cancer. Given the potential of selection bias in the observational studies, randomized trials should be designed to assess the efficacy of metformin use in prostate cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Holman R . Metformin as first choice in oral diabetes treatment: The UKPDS experience. J Annu Diabetol Hotel Dieu 2007, 13–20.

  2. Yin M, Zhou J, Gorak EJ, Quddus F . Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: A systematic review and meta-analysis. Oncologist 2013; 18: 20.

    Google Scholar 

  3. Zhang P, Li H, Tan X, Chen L, Wang S . Association of metformin use with cancer incidence and mortality: A meta-analysis. Cancer Epidemiology 2013; 37: 207–218.

    Article  Google Scholar 

  4. Zhang Z -, Li S . The prognostic value of metformin for cancer patients with concurrent diabetes: A systematic review and meta-analysis. Diabetes Obesity Metab 2014; 16: 707–710.

    Article  CAS  Google Scholar 

  5. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A . Metformin therapy and risk of cancer in patients with type 2 diabetes: Systematic review. PLoS One 2013; 8: e71583.

    Article  CAS  Google Scholar 

  6. Siegel R, Ma J, Zou Z, Jemal A . Cancer statistics, 2014. CA Cancer J Clinicians 2014; 64: 9–29.

    Article  Google Scholar 

  7. Inoki K, Zhu T, Guan KL . TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 115: 577–590.

    Article  CAS  Google Scholar 

  8. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27: 3576–3586.

    Article  CAS  Google Scholar 

  9. Akinyeke T, Matsumura S, Wang X, Wu Y, Schalfer ED, Saxena A et al. Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis 2013; 34: 2823–2832.

    Article  CAS  Google Scholar 

  10. Hammarsten J, Hogstedt B . Hyperinsulinaemia: A prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005; 41: 2887–2895.

    Article  CAS  Google Scholar 

  11. Gapstur SM, Gann PH, Colangelo LA, Barron-Simpson R, Kopp P, Dyer A et al. Postload plasma glucose concentration and 27-year prostate cancer mortality (United States). Cancer Causes Control 2001; 12: 763–772.

    Article  CAS  Google Scholar 

  12. Shen M, Zhang Z, Ratnam M, Dou QP . The interplay of AMP-activated protein kinase and androgen receptor in prostate cancer cells. J Cell Physiol 2014; 229: 688–695.

    Article  CAS  Google Scholar 

  13. He XX, Tu SM, Lee MH, Yeung SC . Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol 2011; 22: 2640–2645.

    Article  Google Scholar 

  14. Patel T, Hruby G, Badani K, Abate-Shen C, McKiernan JM . Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology 2010; 76: 1240–1244.

    Article  Google Scholar 

  15. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 2013; 31: 3069–3075.

    Article  CAS  Google Scholar 

  16. Moher D, Liberati A, Tetzlaff J, Altman DG . PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8: 336–341.

    Article  Google Scholar 

  17. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344–349.

    Article  Google Scholar 

  18. Higgins JPT, Green S (eds). Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]. the Cochrane Collaboration, 2011. available from www.cochrane-handbook.org.

  19. Hayden JA, Coôté P, Bombardier C . Evaluation of the quality of prognosis studies in systematic reviews. Annals of Internal Medicine 2006; 144: 427–437.

    Article  Google Scholar 

  20. van Houwelingen HC, Arends LR, Stijnen T . Advanced methods in meta-analysis: Multivariate approach and meta-regression. Stat Med 2002; 21: 589–624.

    Article  Google Scholar 

  21. Deeks JJ, Macaskill P, Irwig L . The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005; 58: 882–893.

    Article  Google Scholar 

  22. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L . Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol 2008; 61: 991–996.

    Article  Google Scholar 

  23. Review manager (RevMan) [computer program]. Version 5.3. Copenhagen: The Nordic Cochrane centre, the Cochrane Collaboration 2012.

  24. R core team R: A language and environment for statistical computing. RFoundation for statistical computing: vienna, austria, 2013; ISBN 3-900051-07-0, URL: http://www.R-project.org/.

  25. Hitron A, Adams V, Talbert J, Steinke D . The influence of antidiabetic medications on the development and progression of prostate cancer. Cancer Epidemiol 2012; 36: e243–e250.

    Article  CAS  Google Scholar 

  26. Nobes JP, Langley SEM, Klopper T, Russell-Jones D, Laing RW . A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int 2012; 109: 1495–1502.

    Article  CAS  Google Scholar 

  27. Allott EH, Abern MR, Gerber L, Keto CJ, Aronson WJ, Terris MK et al. Metformin does not affect risk of biochemical recurrence following radical prostatectomy: Results from the SEARCH database. Prostate Cancer Prostatic Dis 2013; 16: 391–397.

    Article  CAS  Google Scholar 

  28. Kaushik D, Karnes RJ, Eisenberg MS, Rangel LJ, Carlson RE, Bergstralh EJ . Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol 2014; 32: 43.e1–43.e7.

    Article  CAS  Google Scholar 

  29. Spratt DE, Zhang C, Zumsteg ZS, Pei X, Zhang Z, Zelefsky MJ . Metformin and prostate cancer: Reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013; 63: 709–716.

    Article  CAS  Google Scholar 

  30. Currie CJ, Poole CD, Jenkins-Jones S, Gale EAM, Johnson JA, Morgan CL . Mortality after incident cancer in people with and without type 2 diabetes: Impact of metformin on survival. Diabetes Care 2012; 35: 299–304.

    Article  Google Scholar 

  31. Bensimon L, Yin H, Suissa S, Pollak MN, Azoulay L . The use of metformin in patients with prostate cancer and the risk of death. Cancer Epidemiol Biomarkers Prevention 2014; 23: 13.

    Article  Google Scholar 

  32. Rieken M, Kluth LA, Xylinas E, Fajkovic H, Becker A, Karakiewicz PI et al. Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. World J Urol 2013; 32: 999–1005.

    Article  Google Scholar 

  33. Sanli T, Rashid A, Liu C, Harding S, Bristow RG, Cutz JC et al. Ionizing radiation activates AMP-activated kinase (AMPK): A target for radiosensitization of human cancer cells. Int J Radiat Oncol Biol Phys 2010; 78: 221–229.

    Article  CAS  Google Scholar 

  34. Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM et al. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res 2012; 18: 290–300.

    Article  CAS  Google Scholar 

  35. Jacob BJ, Sutradhar R, Moineddin R, Baxter NN, Urbach DR . Methodological approaches to population based research of screening procedures in the presence of selection bias and exposure measurement error: Colonoscopy and colorectal cancer outcomes in ontario. BMC Med Res Methodol 2013; 13: 2288–13-59.

    Article  Google Scholar 

  36. Wu I, Modlin CS . Disparities in prostate cancer in African American men: What primary care physicians can do. Cleveland Clinic J Med 2012; 79: 313–320.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University, Morgantown, WV, USA

    A D Raval, A Vyas, S Madhavan & U Sambamoorthi

  2. Shrimati Kaumudiniben Health Outcomes Research Group (SKHORG), Dhrangadhra, Gujarat, India

    D Thakker

  3. Department of Surgery/Urology, School of Medicine, West Virginia University, Morgantown, WV, USA

    M Salkini

Authors
  1. A D Raval
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Thakker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Vyas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Salkini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Madhavan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. U Sambamoorthi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A D Raval.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Prostate Cancer and Prostatic Diseases website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Raval, A., Thakker, D., Vyas, A. et al. Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 18, 110–121 (2015). https://doi.org/10.1038/pcan.2014.52

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2014.52

This article is cited by

Search

Advanced search

Quick links